Clearside Biomedical, Inc. (CLSD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CLSD currently has 5.23M outstanding shares. with significant dilution risk as 18.6M authorized shares could dilute existing holders by 355.1%. The company has minimally diluted shareholders by 6.3% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 14, 2025 |
10-Q filing | 5.2M shares outstanding |
5.2M | 19M |
| Sep 12, 2025 |
Stock Split
8-K filing: Stock split 1-for-15 | Outstanding: 77,844,055 → 5,189,603 |
5.2M | 19M |
| Aug 08, 2025 |
10-Q filing | 77.8M shares outstanding |
78M | 280M |
| May 15, 2025 |
10-Q filing | 76.9M shares outstanding |
77M | 280M |
| Mar 27, 2025 |
10-K filing | 73.8M shares outstanding |
74M | 280M |
| Nov 12, 2024 |
10-Q filing | 74.7M shares outstanding |
75M | 280M |
| Aug 12, 2024 |
10-Q filing | 74.7M shares outstanding |
75M | 280M |
| May 10, 2024 |
10-Q filing | 69.9M shares outstanding |
70M | 280M |
| Mar 12, 2024 |
10-K filing | 74.7M shares outstanding |
75M | 280M |
| Nov 13, 2023 |
10-Q filing | 62.0M shares outstanding |
62M | 280M |
| Aug 14, 2023 |
10-Q filing | 61.7M shares outstanding |
62M | 280M |
| May 12, 2023 |
10-Q filing | 61.2M shares outstanding |
61M | 280M |
| May 12, 2023 |
S-3 filing: The company may offer and sell up to $150,000,000 of any combination of common stock, preferred stock, debt securities and/or warrants. |
60M | 280M |
| Mar 14, 2023 |
10-K filing | 60.2M shares outstanding |
60M | 140M |
| Nov 09, 2022 |
10-Q filing | 60.2M shares outstanding |
60M | 140M |
| Aug 12, 2022 |
10-Q filing | 60.2M shares outstanding |
60M | 140M |
| May 12, 2022 |
10-Q filing | 60.2M shares outstanding |
60M | 140M |
| Mar 11, 2022 |
10-K filing | 59.9M shares outstanding |
60M | 140M |
| Nov 10, 2021 |
10-Q filing | 59.7M shares outstanding |
60M | 140M |
| Aug 10, 2021 |
10-Q filing | 59.5M shares outstanding |
59M | 140M |
| May 17, 2021 |
10-Q filing | 57.6M shares outstanding |
58M | 140M |
| Mar 15, 2021 |
10-K filing | 57.4M shares outstanding |
57M | 140M |
| Jan 08, 2021 |
8-K filing: Clearside Biomedical, Inc. entered into a Securities Purchase Agreement with certain institutional purchasers for a registered direct offering of 4,209,050 shares of common stock at $2.851 per share, resulting in gross proceeds of approximately $12 million. ($12.0M proceeds) |
48M | 140M |
| Jan 05, 2021 |
8-K filing: Clearside Biomedical, Inc. sold 4,497,703 shares of its common stock pursuant to its at-the-market sales agreement with Cowen and Company LLC for net proceeds of $9.4 million from October 1, 2020 to January 4, 2021. ($9.4M proceeds) |
48M | 140M |
| Nov 10, 2020 |
10-Q filing | 48.4M shares outstanding |
48M | 140M |
| Aug 10, 2020 |
10-Q filing | 46.3M shares outstanding |
46M | 140M |
| May 19, 2020 |
S-3/A filing: The filing is an S-3/A form indicating a shelf offering of up to $250,000,000 of Common Stock, Preferred Stock, and Debt Securities and also covers an at-the-market offering of common stock up to $50,000,000 through Cowen. |
45M | 140M |
| May 08, 2020 |
S-3 filing: The company is filing an S-3 to register an offering of common stock, preferred stock and debt securities up to a total of $250,000,000. |
45M | 140M |
| May 08, 2020 |
10-Q filing | 44.9M shares outstanding |
45M | 140M |
| Mar 13, 2020 |
10-K filing | 44.9M shares outstanding |
45M | 3.2M |
| Jan 10, 2020 |
S-3 filing: Registration of 3,178,367 shares of common stock for resale by selling stockholders. |
N/A | 3.2M |